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SUMMARY Eighteen patients with congestive heart failure (CHF) complicating coronary artery disease (CAD) and seven patients with CHF due to primary cardiomyopathy (CM) were studied during infusions of dobutamine in doses of 2.5-15.0 ,g/kg/min. There were statistically significant (p < 0.05) improvements in cardiac index, stroke volume index, left ventricular stroke work index and nuclear ejection fraction in both groups. Significant decreases (p < 0.05) in pulmonary capillary wedge pressure, right atrial pressure, and systemic and pulmonary vascular resistances were also observed in both groups. However, five patients increased an already elevated pulmonary capillary wedge pressure during dobutamine infusion, which was associated with either the development of angina pectoris or with a significant elevation of the mean arterial pressure. In the CAD patients, gated cardiac scans analyzed for segmental wall motion showed improvement in 27% of the abnormally contracting segments during dobutamine infusion. Finally, the effects of dobutamine on myocardial metabolism were assessed with arterial and coronary sinus lactate analysis. Fourteen of the 18 CAD patients (78%) showed no metabolic abnormality during dobutamine infusion; four CAD patients (22%), three of whom developed typical angina pectoris, displayed abnormal lactate metabolism. None of the CM patients developed angina pectoris or displayed abnormal lactate metabolism. Of the seven patients with an adverse hemodynamic or metabolic response, four had recently been withdrawn from propranolol therapy. In conclusion, dobutamine produced favorable effects on hemodynamics, left ventricular ejection fraction, and segmental wall motion abnormalities in most patients with CHF without a deleterious effect on myocardial metabolism. DOBUTAMINE is a new inotropic agent, structurally related to other catecholamines, that is used to treat patients with congestive heart failure (CHF) of diverse etiologies. Although studies have shown significant hemodynamic improvements in groups of patients with CHF treated with dobutamine, there has been little effort to discriminate the characteristics of patients who have an adverse hemodynamic response.'1-3 Moreover, few studies have systematically examined whether these hemodynamic changes are at the expense of altering the balance of myocardial oxygen supply and demand. This study was designed to relate the hemodynamic effects of dobutamine to its myocardial metabolic effects in patients with CHF complicating coronary artery disease (CAD), using a group of patients with primary cardiomyopathy (CM) for comparison. In addition, gated cardiac nuclear scans were performed to assess changes in left ventricular ejection fraction (LVEF) and regional wall motion in response to dobutamine.
Methods Subjects
Twenty-five male patients with a clinical history of CHF in whom the mean pulmonary capillary wedge pressure was greater than 12 mm Hg were studied at the time of rightand left-heart catheterization. Patients with a history of unstable angina pectoris or recent myocardial infarction (less than 3 months before the study) and patients with hemodynamically significant valvular, pericardial or pulmonary heart disease were excluded. All /-adrenergic blocking agents, digitalis preparations, diuretics and vasodilators were discontinued at least 24 hours before the study. Informed consent was obtained from all patients.
The study population consisted of 18 patients with CAD and seven with CM. The 18 CAD patients were a mean age of 53.1 years (range 37-67 years). Nine of these patients had clinical or electrocardiographic evidence of a previous myocardial infarction. Coronary arteriography revealed significant (> 70% luminal narrowing) three-vessel disease in 14 patients, two-vessel disease in three, and one-vessel disease in one patient. One patient was in New York Heart Association (NYHA) functional class I1, 12 patients were class Ill, and five were class IV.
The seven CM patients were a mean age of 55.0 years (range 39-74 years), and none had CAD on arteriography. One patient was in NYHA functional class II, three patients were class III, and three were class IV. No patient had a history of angina pectoris or myocardial infarction.
Hemodynamic Observations
A flow-directed, balloon-tipped thermodilution catheter was passed from a right antecubital fossa vein to the pulmonary artery under fluoroscopic control and positioned to obtain a reliable pulmonary capillary ,(edge pressure tracing during balloon inflation. The left brachial artery was cannulated with a Teflon catheter. A Zucker catheter was passed percutaneously from a left antecubital fossa vein to the distal main coronary sinus to avoid reflux, confirmed by both pressure monitoring and a small injection of Renografin-76 during fluoroscopy. Pressures and heart rate (HR) were continuously monitored throughout the study.
Baseline studies included a 12-lead ECG, mean right atrial pressure (RAP), mean pulmonary artery pressure (PAP), mean pulmonary capillary wedge pressure (PCWP), HR, systemic arterial pressure (AP), and cardiac output (CO) done in triplicate by the thermodilution technique. Derived hemodynamic indexes were calculated as follows: cardiac index (CI) = CO/body surface area (I/min/m'); stroke volume index (SVI) = Cl/HR (ml/beat/m2); left ventricular stroke work index (LVSWI) = SVI X (MAP-PCWP) X 0.0136 (g-m/m'); systemic vascular resistance (SVR) = (MAP-RAP)/CO (units); pulmonary vascular resistance (PVR) = Dobutamine was then infused at a rate of 2.5 gg/kg/min, and increased to 5, 10, and 15 pg/kg/min at 30-minute intervals; all hemodynamic measurements were repeated at each dose level. The infusion was discontinued when the PCWP decreased to 8 mm Hg, HR increased to 120 beats/min, mean AP increased to 110 mm Hg (or 20 mm Hg above baseline), or until side effects developed. Thirty minutes after the dobutamine infusion was discontinued, left ventriculography and selective coronary arteriography were performed using the Sones or Judkins techniques.
Metabolic Measurements
Initial laboratory studies of simultaneously drawn arterial and coronary sinus samples were as follows: serum lactate levels (determined in duplicate with the DuPont automatic clinical analyzer according to the modification of the Marbach and Weil method'4) and creatine kinase (including the MB fraction), glutamicoxalacetic transaminase and lactate dehydrogenase. After 30 minutes of stable hemodynamics at each dose level, arterial and coronary sinus samples were again drawn for serum lactate analysis. An abnormal metabolic response was defined as decrease in lactate extraction to 15% or less. At the peak dobutamine dose, cardiac enzymes were repeated. Twelve hours after completion of the study, a repeat ECG and cardiac enzymes were obtained.
Cardiac Scaks
Within 1 week of the catheterization, all 25 patients underwent supine, multiple-gated radionuclide angiography both at rest and with dobutamine infusion at the peak dose established during the initial part of the study. Gated myocardial images were obtained after standard in vivo labeling of red blood cells with 20-25 mCi of i.v. technetium-99m methylene diphosphonate.`Resting supine images were obtained in the anterior and left anterior oblique projections using a conventional Anger scintillation camera (Maxi Camera II, General Electric) with a high-resolution, parallel-hole collimator. LVEF was determined by computer-assisted analysis of left ventricular timeactivity curves using a commercially available nuclear medicine computer system (Med IV, Nova III, General Electric). The left ventricle was divided into anteroseptal, anteroapical, posteroapical and posterolateral segments. Baseline contractility was qualitatively judged to be either hyperkinetic, normal, hypokinetic (mild or moderate), akinetic or dyskinetic. Contractility of these regional wall segments during dobutamine infusion was then compared with the baseline scans. HR and blood pressure were monitored throughout the nuclear study to ensure hemodynamic responses comparable to those obtained in the first part of the study.
Statistical Methods
All data are shown as mean ± SEM. Significance of (PAP-PCWP)/CO (units). between groups was determined by the t test for paired or unpaired data.
Results

Hemodynamics
The baseline hemodynamic findings in the 25 patients are shown in table 1. The mean peak dobutamine dose in the CAD patients was 10.8 ± 0.9 ,ug/kg/min and in the CM patients it was 11.8 ± 0.8 ,ug/kg/min (p = NS). There were statistically significant, progressive increases (p < 0.05) in HR, systolic AP, CI, SVI, LVSWI and LVEF in both groups, and significant decreases (p < 0.05) in the PCWP, RAP, SVR, and PVR in both groups with increasing doses of dobutamine (table 1). The peak values of hemodynamic variables with dobutamine infusion were not statistically different between the two groups.
Seven of the 25 patients were able to tolerate the maximal dobutamine infusion (15 ug/kg/min) without an adverse clinical or hemodynamic response (table 2) . At a dose of 15 ,gg/kg/min, one patient developed chest pain, one became hypertensive and one increased his PCWP. Of the remaining 15 patients, the dobutamine infusion was discontinued at a lower dose because of the development of chest pain (two patients), hypertension (five patients), tachycardia (two patients) or because the PCWP decreased to 8 mm Hg (six patients). In 20 patients (80%), the PCWP decreased with dobutamine administration; in six of these patients (24%), PCWP normalized. In five patients, the PCWP increased above the baseline value during dobutamine infusion and was associated with either a hypertensive response (three patients) or an abnormal metabolic response (two patients). Five patients had increased ventricular ectopic activity compared with baseline, but in no case did this require discontinuing the dobutamine infusion. Three patients (all CAD) had chest pain, which disappeared within minutes after the dobutamine infusion was stopped. 1) . Baseline LVEF and regional wall motion analysis showed a correlation coefficient of 0.86 between contrast ventriculography and radionuclear angiography. With dobutamine infusion, LVEF increased significantly in CAD patients (38.3 ± 4.1%, p < 0.01) and in CM patients (27.9 ± 5.7%, p < 0.005). Dobutamine produced changes in HR and systolic AP during this part of the study that were similar to those noted at catheterization (HR, 95.2 ± 4.9 vs 95.6 ± 4.7 beats/min [p = NS]; systolic AP, 148.4 ± 6.5 vs 163.6 ± 16.3 mm Hg [p = NS], respectively). Two of the three patients who developed angina in the first part of the study also developed angina while receiving dobutamine during nuclear scanning. In the CAD patients, 48 of 72 segments contracted abnormally at rest (table 3) . With dobutamine infusion, 12 of these 48 abnormally contracting segments showed improvement, and in no case was de- terioration of wall motion noted. Of the 24 normally contracting segments at rest, 21% had increased regional contractility during dobutamine infusion. Lactate extraction (arterial-coronary sinus/ arterial concentration) before dobutamine administration was 54.4 ± 5.4% in the CAD group and 60.9 ± 4.2% in the CM group (p = NS). There was a progressive decrease in lactate extraction in both groups with increasing doses of dobutamine ( fig. 1 ). At the peak dobutamine infusion, lactate extraction decreased to 19.1 ± 13.5% in the CAD group (p < 0.005) and 49.4 ± 4.0% in the CM group (p < 0.005). This decrease in lactate extraction was due to a 103% increase in coronary sinus lactate concentration with only a 31% increase in arterial lactate concentration. There were four adverse metabolic responders in the CAD group, three of whom developed typical angina pectoris during dobutamine infusion. Two of these patients became lactate producers (i.e., negative lactate extraction), one patient decreased his lactate extraction from 33% to 3% (a decrease of 91%), and one patient decreased his lactate extraction from 71 % to 15% (a decrease of 79%). No patient in the CM group had chest pain or displayed abnormal lactate metabolism during dobutamine infusion. When these four adverse metabolic responders are excluded, the decrease in lactate production in the other 14 CAD patients was comparable to that in the seven CM patients (25% vs 19%,p = NS) ( fig. 1 ). No patient had electrocardiographic or enzymatic evidence of myocardial damage during or after the study.
Adverse vs Nonadverse Metabolic Responders
There were no significant differences between the four CAD patients who had an adverse metabolic response to dobutamine and the other 14 14 CAD patients (all p = NS). The baseline PCWP, however, was similar in both groups (23.7 vs 23.2 mm Hg). The dose of dobutamine infused was slightly higher in the four adverse responders than in the other 14 CAD patients (12.5 vs 10.4 ,tg/kg/min). The four adverse responders showed a smaller percentage improvement in SVI (6% vs 3 1%), LVSWI (7% vs 63%), and nuclear LVEF (1 3% vs 21 %) in response to dobutamine than the other 14 CAD patients. In addition, the four adverse responders as a group increased their PCWP by 1% (23.7 to 24.0 mm Hg), while the other 14 CAD patients decreased their PCWP by 33% (23.3 to 15.6 mm Hg). The double product of heart rate and systolic AP increased comparably in both groups (41% and 42%), but the four adverse responders had a higher double product during dobutamine infusion than the other 14 CAD patients (163.4 vs 152.5 X l02). Discussion Dobutamine is a catecholamine-derived inotropic agent with predominant f1 adrenergic activity."6 A problem with the use of this class of agents in patients with CAD is their potential ability to increase myocardial oxygen consumption by increasing contractility without producing a sufficient increase in regional myocardial oxygen supply, resulting in ischemia. In the failing heart, the increase in contractility with dobutamine may be offset by reductions in preload or afterload or both, miminizing myocardial oxygen consumption. In patients with noncoronary CM, myocardial oxygen consumption is not limited by anatomic obstruction to coronary blood flow as it is in patients with CAD. With significant coronary artery obstruction, flow distal to the obstruction is dependent on the duration of diastole and on coronary perfusion pressure. '7 In doses that do not produce a significant tachycardia, dobutamine increases coronary perfusion pressure and increases the duration of diastole, and thus would not be expected to produce a significant myocardial oxygen debt.'8 Therefore, when using catecholamine-derived inotropic agents in patients with CAD, metabolic indexes of myocardial oxygen debt and hemodynamic effects must be of equal concern.
In experimental animals with normal coronary arteries and normal resting hemodynamics, there usually are minimal increases in HR and mean AP in response to 5-10-,ug/kg/min doses of dobutamine, but there are consistently more significant increases in coronary blood flow and indexes of left ventricular contractility (e.g., dP/dt and Vmax).19-26 With dobutamine infusion, measured myocardial oxygen consumption is dependent upon the degree of inotropic and chronotropic changes, especially diastolic time, as well as changes in left ventricular filling pressure and systemic resistance. In animals with experimentally induced ischemia, most studies have shown both augmentation of coronary blood flow to ischemic regions and improvement in abnormal hemodynamics with dobutamine administration.17 27, 28 Willerson et al.,28 however, showed that despite an increase in flow to experimentally produced ischemic areas during dobutamine infusion, there were further increases in ST-segment elevations, suggesting increased myocardial injury.
In patients with and without CAD, dobutamine shows dose-dependent increases in coronary blood flow, CO, and left ventricular contractility and, to a lesser extent, HR and mean AP. The increase in mean AP is due predominantly to increase in systolic rather than the diastolic AP. There are concomitant dosedependent decreases in both SVR and PVR.2 29 30 Meyer et al.30 showed that in patients with three-vessel CAD dobutamine produced an inhomogeneity of regional coronary blood flow such that areas supplied by obstructed coronary arteries received proportionately less flow than nonjeopardized regions. Gillespie et al.,31 however, were unable to show any adverse effects on predicted myocardial infarction size in patients with heart failure complicating acute myocardial infarction treated with dobutamine.
In patients with chronic CHF, there is a linear relationship between the plasma dobutamine concentration and a decrease in the PCWP, SVR and PVR, and a linear increase in the CO and SV.'3 Dobutamine, in doses that do not cause tachycardia, has also been shown to improve diastolic time (the percentage of the cardiac cycle spent in diastole when coronary blood flow is maximal) in patients with CHRF. The hemodynamic improvements in our patients given dobutamine are in agreement with previous work.'-"' However, our study shows that despite a significant reduction in the PCWP for the entire group, there were five patients (25%) who increased their already elevated PCWP. Two of these patients developed angina pectoris and abnormal myocardial lactate metabolism with dobutamine infusion, and the other three patients all elevated their mean PCWP in conjunction with an increase of more than 30 mm Hg in their mean AP, probably indicating an afterload stress that exceeded their left ventricular functional reserve. Our study, in addition, shows that there were significant improvements not only in overall LVEF, but also in patterns of segmental wall motion in patients with CAD given dobutamine.
Bleifeld et al.32 reported that in two of four patients with angina pectoris treated with dobutamine, myocardial lactate metabolism changed from that of extraction to that of production, whereas two patients with CHF due to left ventricular aneurysms did not produce lactate. Tubau et al.33 showed that in 16 patients with CHF complicating CAD, dobutamine produced significant increases in coronary sinus blood flow and myocardial oxygen consumption in association with improvements in abnormal hemodynamic variables. The ratio of LVSWI to myocardial oxygen consumption (an index of myocardial oxygen supply and demand) did not significantly increase. No mention was made, however, of whether any patient had an abnormal metabolic response to dobutamine. An adverse metabolic response was not seen in our patients with CM, but did occur in four of 18 (22%) patients with CAD. Although there is controversy as to what constitutes an abnormal lactate response,34 two of our four patients became lactate producers and the other two patients decreased their lactate extraction by 91% and 79%. The latter two patients and one of the lactate producers, moreover, developed angina pectoris in response to dobutamine. The other 14 patients with CAD and the seven patients with primary CM decreased their lactate extraction by 25% and 19%, respectively.
There were no clinical (NYHA functional class and history of myocardial infarction) or angiographic (number of coronary arteries involved, LVEF and regional wall motion abnormalities) variables at baseline that would have predicted an abnormal metabolic response to dobutamine in these four patients. Baseline hemodynamic variables (CI, SVI, LVSWI and SVR), however, did show a trend in these four patients toward less left ventricular dysfunction compared with the other 14 CAD patients. Inotropic agents would thus be expected to produce a greater increase in myocardial oxygen consumption in these patients than in those with more significant cardiac dysfunction.
The doses of dobutamine used in our patients was the maximal tolerated dose in each patient and corresponded to the maximal increase in CO. In patients with CHF, significant hemodynamic improvements have been shown to occur, however, in lower doses (2.5-5.0 ,g/kg/min) without increases in HR or blood pressure. Had these lower doses been used in our patients with CAD and CHF, the incidence of angina pectoris or abnormal lactate metabolism might have been less than the 22% we observed. Finally, only four of the 18 patients with CAD and CHF were taking propranolol. Two of these patients developed chest pain and lactate production, one of whom increased his PCWP during dobutamine infusion. The other two patients increased their PCWP in association with a large increase in their mean AP. Only one other patient increased his PCWP with dobutamine administration and this hemodynamic change occurred concomitantly with the development of chest pain. Thus, it is possible that these adverse metabolic and hemodynamic responses to dobutamine may be accounted for by a hypersensitive response to adrenergic stimulation secondary to propranolol withdrawal.35
Conclusion
In 18 patients with CAD and CHF and seven patients with nonischemic congestive CM, dobutamine produced favorable effects on abnormal hemodynamics, LVEF and segmental wall motion abnormalities. However, five patients had a"'paradoxic" increase in left ventricular filling pressure associated with the development of significant hypertension or an abnormal metabolic response. Fourteen of the 18 CAD patients (78%), even with doses of dobutamine that produced significant increases in HR and systolic blood pressure, nevertheless showed no metabolic abnormalities. Four SUMMARY Digoxin (5 mg/mI) was added to 10-mg and 20-mg pellets of purified primary and secondary amyloid fibrils, a normal human liver and heart homogenate and a homogenate from the heart of a patient with amyloid cardiomyopathy who had not received digitalis. After centrifugation, the supernatants were recovered and assayed for digoxin concentrations. Aliquots from the sediments were studied for the presence of digoxin, using rabbit antidigoxin antiserum and an indirect immunofluorescent technique. The results showed that 0.11-0.13 ng/ml of digoxin bound per milligram of fibrils and could not be separated by repeated washings. elution with citrate or changes in the pH of the buffer. Immunofluorescent studies demonstrated diffusely bright immunofluorescence with the fibril preparation and amyloid heart homogenate when reacted with digoxin and digoxin-specific antiserum. These studies demonstrate that isolated amyloid fibrils bind digoxin and suggest that this interaction may play some role in the sensitivity to digitalis that has been observed in some patients with amyloid cardiomyopathy. THE PATHOPHYSIOLOGIC ABNORMALITIES that result from amyloid deposition are thought to be caused by replacement of functional tissue by the amyloid fibrils, which have been considered to be inert.' However, the affinity of the amyloid fibril for various dyes, including Congo red2 and Alcian blue,3 and the recent studies that show selective binding to amyloid fibrils of certain proteins, i.e., P-component,4 blood clotting factors5 and the bone-seeking radionuclide technetium methylene diphosphonate,6 suggest that the fibrils may play a more complex role in various organs.
All clinical forms of amyloidosis can involve the heart.' Patients with amyloid cardiomyopathy are allegedly sensitive to digitalis7 8 which may cause abrupt changes in cardiac rhythm or sudden death. In an effort to understand why digitalis preparations could affect the amyloid-laden heart, an in vitro study was carried out to assess the interaction of isolated amyloid fibrils and digoxin, and in particular, to determine whether isolated amyloid fibrils bind digoxin.
Methods
Fibril Preparation
Amyloid fibrils were isolated from the spleens of two patients with primary amyloidosis and one with secondary amyloidosis as described elsewhere.9 The fibrils were washed three times in Tris-buffered saline (TBS) 0.01 M, pH 8.0, containing 10 mM EDTA to free them from any calcium-bound proteins. They were then dialyzed exhaustively against distilled water and lyophilized.
Digoxin Preparations and Assays
Digoxin, 1 mg/ml (Lanoxin, Burroughs Wellcome) was diluted in deionized water to a concentration of
